Relmada Therapeutics (NASDAQ: RLMD) updates shareholder letter and corporate deck

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. filed a current report to share updated communications with investors. On September 10, 2025, the company issued a letter to shareholders describing its recent progress, which is furnished as Exhibit 99.1. On the same date, Relmada also updated its corporate presentation, furnished as Exhibit 99.2. The company notes that these materials are provided under Regulation FD and are considered "furnished" rather than "filed" under securities laws, meaning they are not automatically incorporated into other SEC filings unless specifically referenced.

false 0001553643 0001553643 2025-09-10 2025-09-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2025

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-39082		45-5401931
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL		33134
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (786) 629-1376

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common stock, $0.001 par value per share		RLMD		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01 Regulation FD Disclosure.

On September 10, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a letter to its shareholders providing an update on the Company’s recent progress, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

On September 10, 2025, the Company also updated its corporate presentation, a copy of which is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1*		Letter to Shareholders dated September 10, 2025
99.2*		Corporate Presentation dated September 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 10, 2025	RELMADA THERAPEUTICS, INC.
	By:	/s/ Sergio Traversa
	Name:	Sergio Traversa
	Title:	Chief Executive Officer

2

FAQ

What did Relmada Therapeutics (RLMD) disclose in this 8-K?

Relmada Therapeutics disclosed that it issued a shareholder letter and an updated corporate presentation on September 10, 2025, which are furnished as Exhibits 99.1 and 99.2.

What is included in Exhibits 99.1 and 99.2 for Relmada Therapeutics (RLMD)?

Exhibit 99.1 is a Letter to Shareholders dated September 10, 2025, and Exhibit 99.2 is a Corporate Presentation dated the same day.

Are the Relmada Therapeutics shareholder letter and presentation considered filed with the SEC?

The company states that the information in Item 7.01 and Exhibits 99.1 and 99.2 is being furnished, not filed, under the Exchange Act, except where specifically incorporated by reference.

Under which SEC item did Relmada Therapeutics (RLMD) provide this information?

The information about the shareholder letter and corporate presentation is provided under Item 7.01, Regulation FD Disclosure.

When were Relmada Therapeutics’ updated shareholder materials dated?

Both the Letter to Shareholders and the Corporate Presentation are dated September 10, 2025.

Who signed this Relmada Therapeutics (RLMD) 8-K report?

The report was signed on behalf of Relmada Therapeutics, Inc. by Sergio Traversa, Chief Executive Officer, dated September 10, 2025.